AR058033A1 - PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS - Google Patents
PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMSInfo
- Publication number
- AR058033A1 AR058033A1 ARP060103880A ARP060103880A AR058033A1 AR 058033 A1 AR058033 A1 AR 058033A1 AR P060103880 A ARP060103880 A AR P060103880A AR P060103880 A ARP060103880 A AR P060103880A AR 058033 A1 AR058033 A1 AR 058033A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- lecozotan
- cmax
- formulations
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Formulaciones y métodos para el suministro de 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida, sales farmacéuticamente aceptables de la misma, compuestos estructuralmente relacionados y/o metabolitos; así como también a la utilizacion de estas formulaciones y métodos para tratar una enfermedad. Reivindicacion 1: Un método que comprende administrar a un paciente una forma de dosificacion oral que comprende lecozotan y un portador farmacéuticamente aceptable y que alcanza una concentracion en plasma máxima (Cmáx) en un paciente y una concentracion en plasma de 24 horas (C24) en un paciente, en donde una relacion media de Cmáx/C24 en una poblacion de pacientes es desde aproximadamente 5:1 hasta aproximadamente 1,1:1. Reivindicacion 57: Un método para tratar la enfermedad de Alzheimer en un paciente caracterizado porque comprende administrar al paciente una formulacion de liberacion sostenida de lecozotanFormulations and methods for the delivery of 4-cyano-N - {(2R) -2- [4- (2,3-dihydro-benzo [1,4] dioxin-5-yl) -piperazin-1-yl] - propyl} -N-pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and / or metabolites; as well as the use of these formulations and methods to treat a disease. Claim 1: A method comprising administering to a patient an oral dosage form comprising lecozotan and a pharmaceutically acceptable carrier and reaching a maximum plasma concentration (Cmax) in a patient and a 24 hour plasma concentration (C24) in a patient, where an average ratio of Cmax / C24 in a population of patients is from about 5: 1 to about 1.1: 1. Claim 57: A method for treating Alzheimer's disease in a patient characterized in that it comprises administering to the patient a sustained release formulation of lecozotan
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71541705P | 2005-09-09 | 2005-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058033A1 true AR058033A1 (en) | 2008-01-23 |
Family
ID=37836444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103880A AR058033A1 (en) | 2005-09-09 | 2006-09-06 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1928863A2 (en) |
JP (1) | JP2009507850A (en) |
KR (1) | KR20080043855A (en) |
CN (1) | CN101258146A (en) |
AR (1) | AR058033A1 (en) |
AU (1) | AU2006287543A1 (en) |
BR (1) | BRPI0615771A2 (en) |
CA (1) | CA2620491A1 (en) |
CR (1) | CR9800A (en) |
EC (1) | ECSP088236A (en) |
GT (1) | GT200600403A (en) |
IL (1) | IL189827A0 (en) |
NO (1) | NO20081100L (en) |
PE (1) | PE20070334A1 (en) |
RU (1) | RU2008108216A (en) |
TW (1) | TW200800198A (en) |
WO (1) | WO2007030589A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
CN101553217A (en) | 2005-07-06 | 2009-10-07 | 塞普拉科公司 | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment |
JP2012526832A (en) * | 2009-05-13 | 2012-11-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Composition comprising transnorsertraline and serotonin receptor 1A agonist / antagonist and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL203217B1 (en) * | 2000-09-29 | 2009-09-30 | Solvay Pharm Bv | Ion-strength independent sustained release pharmaceutical formulation |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
CN101137648A (en) * | 2005-03-01 | 2008-03-05 | 惠氏公司 | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin -1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
-
2006
- 2006-09-06 PE PE2006001076A patent/PE20070334A1/en not_active Application Discontinuation
- 2006-09-06 EP EP06790193A patent/EP1928863A2/en not_active Withdrawn
- 2006-09-06 CA CA002620491A patent/CA2620491A1/en not_active Abandoned
- 2006-09-06 WO PCT/US2006/034813 patent/WO2007030589A2/en active Application Filing
- 2006-09-06 KR KR1020087007106A patent/KR20080043855A/en not_active Application Discontinuation
- 2006-09-06 AR ARP060103880A patent/AR058033A1/en unknown
- 2006-09-06 JP JP2008530186A patent/JP2009507850A/en not_active Withdrawn
- 2006-09-06 AU AU2006287543A patent/AU2006287543A1/en not_active Abandoned
- 2006-09-06 CN CNA2006800328607A patent/CN101258146A/en active Pending
- 2006-09-06 TW TW095132852A patent/TW200800198A/en unknown
- 2006-09-06 GT GT200600403A patent/GT200600403A/en unknown
- 2006-09-06 BR BRPI0615771-8A patent/BRPI0615771A2/en not_active Application Discontinuation
- 2006-09-06 RU RU2008108216/14A patent/RU2008108216A/en not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189827A patent/IL189827A0/en unknown
- 2008-03-03 NO NO20081100A patent/NO20081100L/en not_active Application Discontinuation
- 2008-03-04 EC EC2008008236A patent/ECSP088236A/en unknown
- 2008-03-07 CR CR9800A patent/CR9800A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2620491A1 (en) | 2007-03-15 |
CR9800A (en) | 2008-04-28 |
CN101258146A (en) | 2008-09-03 |
RU2008108216A (en) | 2009-10-20 |
AU2006287543A1 (en) | 2007-03-15 |
BRPI0615771A2 (en) | 2011-05-24 |
PE20070334A1 (en) | 2007-05-08 |
TW200800198A (en) | 2008-01-01 |
EP1928863A2 (en) | 2008-06-11 |
ECSP088236A (en) | 2008-04-28 |
WO2007030589A2 (en) | 2007-03-15 |
KR20080043855A (en) | 2008-05-19 |
NO20081100L (en) | 2008-06-03 |
JP2009507850A (en) | 2009-02-26 |
WO2007030589A3 (en) | 2007-11-01 |
IL189827A0 (en) | 2008-11-03 |
GT200600403A (en) | 2007-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201170969A1 (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
NO20061859L (en) | OROS Push Stick for controlled delivery of active agents | |
ECSP066866A (en) | DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS REFERENCE TO RELATED APPLICATIONS | |
ECSP045140A (en) | Pharmaceutical formulations derived from platinum | |
CY1112376T1 (en) | 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists | |
AR059723A2 (en) | COMPOSITION OF HIGH DOSE OF IBANDRONATO | |
NO20052914L (en) | Therapeutic compounds | |
AR048336A1 (en) | HYDROCLORIDE OF (4- (5-AMINOMETIL-2-FLUORO-PHENYL) -PIPERIDIN-1-IL) - (4-BROMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE | |
CR20130263A (en) | ACTIVE CANABINOID PHARMACEUTICAL INGREDIENT FOR IMPROVED DOSE FORMS (RECORD DIVISIONAL N ° 9662) | |
AR045289A1 (en) | ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
EA200602016A1 (en) | POWDER COMPOSITIONS FOR INHALATION CONTAINING ENANTIOMERNA CLEAN AGENTISTS | |
CY1110450T1 (en) | USE OF A HYDROXIMIC ACID ALLOGONIDE PRODUCER IN THE TREATMENT OF NEUROLOGICAL DISEASES | |
AR035603A1 (en) | DERIVATIVES OF PIPERAZINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AS SEROTONERGIC AGENTS | |
DE602004015603D1 (en) | PYRAZOLOÄ3,4-BÜPYRIDIN-6-ONE AS GSK-3 INHIBITORS | |
DE602004015406D1 (en) | USE OF 3-METHOXY-PREGNENOLONE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
UY29823A1 (en) | SUBSTITUTED DERIVATIVES OF 7-CHLORINE-3H-IMIDAZOL- (4,5-B) PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THE PREPARATION OF THE SAME AND APPLICATIONS | |
AR043259A1 (en) | METHOD FOR THE TREATMENT OF SEVERE CARDIAC INSUFFICIENCY AND MEDICATION FOR IT | |
RU2009123536A (en) | Stable parenteral formulations, including benzodiazepine-based PCB inhibitors | |
HUP0100024A2 (en) | Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient | |
AR058033A1 (en) | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | |
AR059838A1 (en) | FORMULATIONS FOR STABILIZING DOSES OF STATIN | |
DE50312523D1 (en) | Pharmaceutical Composition and its use | |
WO2017041112A1 (en) | Ketamine and cytochrome p 450 inhibitor combinations | |
AR037711A1 (en) | CITRIC ACID SALT OF A THERAPEUTIC COMPOUND AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
ME00154B (en) | Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |